Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street's expectations, but shares fell hard in after-hours trading, in an echo of ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Consumer Reports looked at how weight loss drugs and possible side effects in older adults.

Weight loss drugs quickly became the go-to tactic for celebrities like Fat Joe, Kathy Bates, Macy Gray, Kelly Clarkson, Rebel ...

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, ...

Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth ...

MarketWatch was able to verify Zeng's claims via videos and was also able to order delivery of Ozempic to an address in China. The price was 798 yuan ($108) for a one-month supply that is injected ...

Obesity trends have stayed stable in the last couple years, whereas severe obesity has trended downward, a recently published report suggested.However, the percentage of people with a healthy weight ...

Hims & Hers said the U.S. FDA's decision that the shortage of Novo Nordisk's weight-loss and diabetes drugs had been resolved ...

Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...

As women strive to understand and openly discuss the changes that impact every cell of their bodies, and new research shows ...